INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most frequent pediatric cancer, with risk-targeted treatment regimens curing ALL in more than 80% of patients. 1 Fractures due to osteoporosis are an important complication of childhood leukemia at diagnosis, as well as during and after ALL therapy.
2- 10 We recently found that 16% of children with recently diagnosed ALL had vertebral fractures and that half of the children manifested moderate or severe fractures. Furthermore, each standard deviation (SD) reduction in spine bone mineral density (BMD) Z-score was associated with an 80% increased odds of vertebral fractures.
11
To date, the incidence of vertebral fractures after the initiation of chemotherapy has not been reported. This is an important consideration because children with ALL receive osteotoxic medications such as glucocorticoids and methotrexate, both of which may further compromise bone strength. 12 In the present study, we describe the incidence of vertebral fractures in children with ALL in the year after chemotherapy initiation and evaluate the associated clinical factors.
PATIENTS AND METHODS

Patients and Study Design
Patients were recruited through pediatric oncology clinics in 10 children's hospitals across Canada as part of
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the STeroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program. Children from 1 month to 17 years of age with ALL were enrolled (N ϭ 188) from 2005 to 2007, with the baseline bone health assessment initiated within 30 days of glucocorticoid therapy. 11 The study was approved by the ethics board in each institution and informed consent/assent were obtained, as appropriate. Children were excluded from the study if they had received treatment with a bisphosphonate or calcium and vitamin D supplementation that exceeded the dietary reference intake for age.
11
Clinical Data
All children were treated according to Children's Oncology Group (nine sites) or the Dana-Farber Cancer Institute (one site) protocols. Clinical data were obtained at baseline and every 3 months after the baseline assessment for a total of 12 months. Height, weight, and pubertal staging according to Marshall and Tanner 13, 14 were determined as previously described. 11 Height, weight, and body mass index (weight [in kilograms] divided by height [in square meters]) raw values were transformed into age-and sex-matched Z-scores according to the US Centers for Disease Control National Center for Health Statistics normative database 15 ; for children younger than 2 years, body mass index Z-scores were calculated according to the WHO child growth standards. 16 The presence or absence of back pain reported by the participant was recorded at each study visit, and the spine was palpated for tenderness at baseline and at 12 months. For nonverbal children, the history of back pain was obtained from the caregiver.
Dietary calcium and vitamin D intake were assessed by a validated food frequency questionnaire. 17 Daily intake (diet plus supplement) was expressed as the percentage of the adequate intake value based on dietary reference intakes. 18 The percentage of adequate intake scores was then classified as less than 50% of the age-related dietary reference intake, Ն 50 and less than 100%, or Ն 100% of the reference intake. Physical activity was assessed through the Habitual Activity Estimation Scale.
11,19,20
Quantification of Glucocorticoid and Methotrexate Exposure
The dose of systemic glucocorticoid therapy (oral and intravenous) received during the 12-month observation period was converted into prednisone equivalents expressed as [21] [22] [23] : (1) cumulative glucocorticoid dose, the amount in prednisone equivalents (milligrams per square meter) received during the observation period; (2) average glucocorticoid dose, the cumulative dose in prednisone equivalents divided by the total number of days during the observation period; and (3) glucocorticoid dose-intensity, the cumulative dose in prednisone equivalents divided by the number of days in receipt of steroids during the observation period. Methotrexate was quantified by summing the cumulative dose over the observation period.
Vertebral Fracture Assessment
Lateral thoracolumbar spine radiographs were obtained at baseline and 12 months, with vertebral fracture assessment based on the Genant semiquantitative method from T4 to L4. 24 Vertebral bodies were graded according to the extent of the difference in height ratios from 100% when the anterior vertebral height was compared with the posterior height, the middle height to the posterior height, and the posterior height to the posterior height of adjacent vertebral bodies. The scores corresponded to the following differences in height ratios: grade 0, 20% or less (normal); grade 1 fracture (mild), more than 20% to 25%; grade 2 fracture (moderate), more than 25% to 40%; grade 3 fracture (severe), more than 40%. Minimal physiologic rounding of vertebral bodies in the midthoracic region of the spine, as can be seen in normal children, was assigned a grade 0 score. 25, 26 An incident vertebral fracture was defined as an increase in the Genant grade of at least one compared with baseline.
Lumbar Spine BMD by Dual-Energy X-Ray Absorptiometry, Bone Age, and Second Metacarpal Morphometry BMD was measured in the anterior-posterior direction at the lumbar spine (L1 to L4) by dual-energy x-ray absorptiometry using either Hologic (Hologic, Bedford, MA; QDR 4500, three centers; Discovery, two centers; Delphi, one center) or Lunar Prodigy (GE Lunar Corporation, Madison, WI; four centers) systems at baseline and at 6 and 12 months. Machines were cross-calibrated as previously described.
11 Data were converted to Hologic units, and Z-scores were generated using the Hologic 12.4 normative database, a database provided by the manufacturer that spans the age ranges included in this study. Radiographs of the left hand and wrist were obtained at baseline and 12 months to determine bone age and second metacarpal percent cortical area, as previously reported.
11
Statistical Analyses
Categorical variables were summarized using frequency and percentage. Continuous variables were summarized using mean and SD or median (25th 
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For data expressed as percentages, the denominator is 155 children unless otherwise specified.
†Combined dietary plus supplemental intake, expressed as the % of the dietary reference intake for age.
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www.jco.org percentile, 75th percentile, or minimum, maximum). The 95% CIs for the proportions of patients with vertebral deformities were calculated using the Wilson score method.
27
Differences between those with and without incident vertebral fracture were assessed using a 2 or Fisher's exact test for categorical variables and a t test or a nonparametric (Wilcoxon Mann-Whitney) test for continuous variables, as appropriate. Multivariable logistic regression was performed to identify clinical variables significantly associated with incident vertebral fracture after adjusting for the variables in the model. To address over-fitting of models, the variables included in the models were identified using a two-step process. First, the variables that were statistically significant based on univariate testing were assessed. This first step considered at least five events per variable, an approach supported by Vittinghoff and McCulloch. 28 The second step was to add nonsignificant but nevertheless clinically important variables, to demonstrate that such covariates were considered in the models. Vittinghoff and McCullogh 28 found a low risk of bias with five to nine events per outcome variable in logistic regression models, and this formed the basis for the sample size used for the models in this article.
For the models that included vertebral fractures in children at baseline as a predictor variable, covariance analysis was used. Model discrimination was assessed using the c statistic (equivalent to the area under the receiver operating characteristic curve), which refers to the ability of the model to distinguish between those children having a higher risk of sustaining incident vertebral fractures versus those with lower risk. 29 The c statistic between 0.7 and 0.8 is consistent with acceptable model discrimination; 0.8 to 0.9 is an indication of excellent discrimination. Reported P values are two-sided, and a P value less than .05 was considered statistically significant. Analyses were conducted using SPSS 18.0 (SPSS, Chicago IL).
RESULTS
Clinical Characteristics of the Cohort
A total of 368 children were approached for participation in the study; 161 declined and 19 were excluded because of failure to undergo a bone health evaluation within the baseline timeline. Of these 188 children, 155 completed follow-up to 12 months ( Table 1) . The reasons for lack of available data on 33 children at 12 months are presented in Figure 1 . The clinical profile at baseline for the 33 children without data at 12 months did not differ significantly from those with complete follow-up (data not shown).
For the 155 children who completed the 12-month data collection, the baseline spine BMD was carried out at a median of 15 days from glucocorticoid initiation (interquartile range [IQR], 5 to 22), and the baseline spine radiograph was carried out at a median of 20 days (IQR, 10.5 to 25.5). Children with prevalent vertebral fractures at baseline (n ϭ 25) had a similar number of days between glucocorticoid initiation and the spine radiograph (median, 20 days; IQR, 6.5 to 26) compared with those without baseline vertebral fractures (median, 19.5 days; IQR, 11.25 to 25; P ϭ .642). Similarly, the cumulative glucocorticoid dose up until the time of the baseline spine radiograph was similar for children with baseline vertebral fractures (median, 890 mg/m 2 ; IQR, 200 to 1064) compared with those without (median, 877 mg/m 2 ; IQR, 514 to 1134; P ϭ .369). The percentage of children in Tanner stage 1 pubertal development at 12 months was 76%, with 24% in stages 2 to 5. Mean height Z-scores were lower at 12 months (mean Ϯ SD, Ϫ0.1 Ϯ 1.2) compared with baseline (0.3 Ϯ 1.2; P Ͻ .001), whereas weight Z-scores were higher (0.5 Ϯ 1.2 at 12 months v 0.4 Ϯ 1.3 at baseline; P ϭ .03), resulting in increased body mass index Z-scores (0.9 Ϯ 1.1 at 12 months v 0.4 Ϯ 1.5 at baseline; P Ͻ .001).
Vertebral Fractures
Twenty-five of the 155 children (16%; 95% CI, 11% to 23%; 14 boys) sustained 61 incident vertebral fractures. None reported trauma. Fifty-two (85%) of the 61 incident vertebral fractures were in previously normal vertebral bodies, whereas nine were worsening of existing fractures. Twelve children (48%) had mild fractures as the worst grade, eight (32%) had moderate fractures, and five (20%) sustained severe incident fractures. Representative fractures are shown in Figures 2A and 2B . Thirteen children (52%) had a single vertebral fracture, seven had two to three fractures (28%), and five children had four to 10 incident fractures (20%). These five children had 31 (51%) of the total number of incident fractures. Fractures were clustered in the midthoracic region (38% from T5 to T7) and thoracolumbar junction (21% from T12 to L2), and 52% of the incident vertebral fractures were moderate or severe.
Differences in the Clinical Profiles of Children With and Without Incident Vertebral Fractures
The two groups did not differ significantly in age, sex, anthropometry, methotrexate or glucocorticoid exposure, leukemia immunophenotype or risk category, white blood count, physical activity, second metacarpal percentage cortical area Z-score, or total calcium and vitamin D intake (Table 2) . However, more than 50% of children with incident vertebral fractures had fractures at baseline. Furthermore, the 13 children with both incident fractures as well as prevalent fractures at baseline carried most of the 12-month incident fracture burden, harboring 45 (74%) of 61 of the incident fractures. The percentage of children with incident fractures at 12 months was highest among those with more severe fractures at baseline: 12 (9%) of 130 children without fractures at baseline had incident vertebral fractures at 12 months compared with five (45%) of 11 children with grade 1 fractures, four (44%) of nine children with grade 2 fractures, and four (80%) of five children with grade 3 fractures (P Ͻ .001).
The mean spine BMD Z-score was significantly lower in children with incident vertebral fractures compared with those without at baseline and at 6 and 12 months (Fig 3) . The mean change in spine BMD Z-score was similar between the two groups from baseline to 12 months (Table 2) ; however, children with incident vertebral fractures had greater increases in spine BMD Z-scores between 6 and 12 months.
Clinical Variables Associated With Increased Odds of Incident Vertebral Fracture
Logistic regression models were fit to examine factors associated with increased odds of incident vertebral fracture at 12 months for the entire cohort (models 1 through 3; n ϭ 155) and for the subset of children who did not have vertebral fractures at baseline (model 4; n ϭ 130). For all models, the dependent variable was a yes/no indicator defined as yes for children who had at least one incident vertebral fracture at 12 months.
The results of model 1 (Fig 4) showed that the presence of at least one vertebral fracture at baseline was highly associated with increased odds of a child sustaining at least one incident vertebral fracture at 12 months (c statistic ϭ 0.78; 95% CI, 0.67 to 0.90). Other variables included in this model were spine BMD Z-score, back pain, and age (all at baseline), as well as sex and cumulative glucocorticoid dose. Model 2 (c statistic ϭ 0.74; 95% CI, 0.63 to 0.85) was generated by excluding vertebral fractures at baseline from model 1. In this model, baseline spine BMD Z-score was associated with increased odds of incident vertebral fracture, as follows: For every one SD reduction in spine BMD Z-score at baseline, the odds of incident vertebral fracture increased 1.8-fold (95% CI, 1.2 to 2.7; P ϭ .006). In model 3 (c statistic ϭ 0.78; 95% CI, 0.67 to 0.90), the presence of vertebral fractures at baseline was replaced with the highest Genant grade at baseline. Both the presence of grade 1 vertebral fractures (odds ratio, 7.6; 95% CI, 1.8 to 31.8; P ϭ .006) and the presence of grade 2 and 3 fractures (odds ratio, 7.0; 95% CI. 1.6 to 30.2; P ϭ .009) were associated with an increased odds of sustaining at least one incident vertebral fracture.
The and cumulative glucocorticoid dose, back pain was associated with 9.2-fold increased odds of incident vertebral fractures (95% CI, 1.6 to 51.7; P ϭ .012). Children with incident vertebral fractures in the absence of fractures at baseline had greater increases in body mass index Z-scores from baseline to 12 months compared with those without fractures at either time point (mean Ϯ SD ϭ ϩ1.1 Ϯ 1.5 v ϩ0.5 Ϯ 0.9; P ϭ .043).
DISCUSSION
We found that 16% of children with ALL developed incident vertebral fractures 12 months after the initiation of therapy. The presence of low spine BMD Z-score or vertebral fractures of any grade were associated with significantly increased odds of incident vertebral fractures. That an initial vertebral fracture is associated with increased odds of a subsequent fracture has not been previously reported in children. However, the phenomenon is well-known among adults, 30,31 described as the so-called vertebral fracture cascade.
32 Among postmenopausal women, vertebral fracture at an initial time point is associated with five-fold increased relative risk for incident vertebral fracture 12 months later. 31 Our observation that every one SD reduction in spine BMD Z-score at baseline was associated with an 80% increased odds of incident vertebral fracture is also aligned with adult studies.
33,34
Our results did not show a relationship between glucocorticoid or methotrexate dose and incident vertebral fracture. Retrospective studies in pediatric ALL have shown a relationship between these agents and skeletal morbidity after 5 to 10 years of follow-up, 3, 6, 35 including an increase in long-bone fractures. 4 Interestingly, in our study the children with incident vertebral fractures in the absence of fractures at baseline had greater increases in body mass index over the 12-month period, an observation that suggests clinically important variability in glucocorticoid sensitivity may be mediated by differences in glucocorticoid pharmacokinetics or pharmacogenomics among patients. 36 The absence of a link to glucocorticoid or methotrexate dose in our study could also reflect the relatively small number of children with vertebral fractures, particularly in view of the standardized chemotherapy protocols. Similarly, we did not find any differences in leukemia variables (eg, WBC) for children with incident vertebral fractures compared with those without, an observation that could also have been impacted by sample size.
That a subset of children had a disproportionate number of prevalent fractures at baseline plus incident fractures at 12 months raises the possibility of genetic susceptibility to bone fragility in these particular children. Our data also suggest that the determinants of compromised bone strength leading to fracture may be different early in the course of leukemia therapy compared with later. At ALL diagnosis, bone fragility has been linked to excessive skeletal resorption through liberation of osteoclast-activating factors by the leukemic cells (including interleukins 6 and 8).
37 This observation is supported by our data showing excessive osteolysis on the second metacarpal endosteal surface among children with vertebral fractures and recently diagnosed ALL, resulting in reduced metacarpal cortical width.
11
Vassilopoulou-Sellin and Ramirez 38 reported a young patient with ALL with back pain and subtle vertebral changes at diagnosis followed by severe vertebral fractures just 2 months later. A transiliac bone biopsy showed signs of prior, accelerated resorption that had resolved by 2 months. Our data showing that children with incident vertebral fractures at 12 months had greater increases in spine BMD Z-scores between 6 and 12 months also suggests the 12-month incident vertebral fractures may have occurred early in the observation period and were then followed by a degree of recovery manifesting as enhanced BMD accrual. In contrast, studies that have shown a relationship between glucocorticoid exposure and skeletal morbidity after 5 to 10 years of follow-up 3, 6, 35 suggest that medication-induced osteotoxicity may take time to manifest clinically.
A key clinical question is whether children with ALL and vertebral fractures in the first year of therapy should be treated with osteoporosis agents such as bisphosphonates. To date, there have been no randomized, placebo-controlled trials in pediatric ALL to provide Results of logistic regression model 1 showing that the presence of at least one vertebral fracture at baseline was highly associated with increased odds of a child sustaining at least one incident vertebral fracture at 12 months. BMD, bone mineral density; GC, glucocorticoid; OR, odds ratio.
adequate safety and efficacy data and thereby justify the use of such agents as standard of care. It is possible that bisphosphonates could treat the low BMD and also stabilize vertebral fractures in this context by influencing the early ALL effects on the skeleton, just as bisphosphonates are effective in the cytokine-induced bone disease of multiple myeloma. 39 If later adverse bone manifestations in ALL are chemotherapy-related, bisphosphonates might also be effective, as their benefits are well-documented in the treatment of adult glucocorticoid-induced osteoporosis. 39 It will be important that any future osteoporosis treatment studies in pediatric ALL consider that the mechanisms underlying bone disease may be different early after disease presentation compared with later or even after completion of chemotherapy. 
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